Opzelura is a brand-name prescription medication used to treat atopic dermatitis and vitiligo [1]. The National Drug Code (NDC) is a unique 10-digit identifier for human drugs that is used in the United States. Different strengths and formulations of Opzelura will have different NDC numbers.
What is the NDC for Opzelura?
The NDC for Opzelura varies depending on the specific product and packaging. For example, Opzelura cream 1.5% in a 60-gram tube has an NDC of 51759-024-60 [2].
What is Opzelura used for?
Opzelura (ruxolitinib cream) is indicated for the topical treatment of nonsegmental vitiligo and atopic dermatitis [1]. It is approved for patients 12 years of age and older [1].
How does Opzelura work?
Opzelura contains ruxolitinib, which is a Janus kinase (JAK) inhibitor. By inhibiting JAK enzymes, ruxolitinib helps to reduce inflammation and itching associated with atopic dermatitis and repigmentation in vitiligo [1].
What are the potential side effects of Opzelura?
Common side effects of Opzelura include upper respiratory tract infections, itching, diarrhea, and worsening of atopic dermatitis [1]. More serious side effects can occur, and patients should discuss these risks with their healthcare provider.
What is the patent status of Opzelura?
Information on drug patents, including those for Opzelura, can be found on DrugPatentWatch.com [3]. Patents for drugs play a crucial role in determining market exclusivity and the eventual availability of generic alternatives.